Meinsterernst for antibodies, R. whether LUZP1 includes a role in the establishment of the conversation between ATAC and MED, we purified the ATAC complex from mESCs derived from knockout mice (Lee et al, 2001) and decided the quantity of the MED remaining associated with ATAC (Fig 3B). In function of the ATACCMED complex, we undertook chromatin immunoprecipitation against LUZP1 and GCN5 followed by high-throughput sequencing (ChIP-seq) to determine the common loci to which the LUZP1-made up Oxcarbazepine of ATACCMED complex binds. After bioinformatics analysis, 46 LUZP1 binding sites were identified with high confidence, which most probably represented only the most significant LUZP1 binding events. This low number might be because of the dynamic behaviour of LUZP1 limiting its crosslinking to chromatin. When comparing these LUZP1 binding sites with those of the genome-wide GCN5 density map obtained after ChIP-seq using mESCs, we observed that most LUZP1 sites lack GCN5, indicating that LUZP1 could also be detected around the genome in an ATACCMED-independent manner (group I, Fig 4A). When the genome-wide LUZP1 binding sites were compared with those bound by GCN5 and Pol II (available from mESCs for Pol II; Mikkelsen et al, 2007), we identified a number of sites that were bound by all three factors (group II, Fig 4A). In agreement with the three ChIP-seq Oxcarbazepine data sets, our ChIP-quantitative PCR (CRIP-qPCR) validation indicated that these sites were bound by LUZP1, GCN5, Pol II and MED1 (Fig 4C). Surprisingly, we observed that all the identified, bound genes belong to the family of genes expressing unspliced ncRNAs (Fig 4B), most of them being small nuclear RNA (snRNA) genes. To investigate how general is the recruitment of MECO subunits on snRNA promoters, we systematically analysed GCN5, Pol II and LUZP1 levels at all mouse snRNA promoters. We observed that this relevant GCN5 levels are detected systematically at active Pol II-transcribed snRNA promoters, indicating that the regulation of the expression of snRNAs by MECO would be a widespread mechanism (supplementary Fig S3 online). Open in a separate window Physique 4 The Ada-Two-A-containingCMediator meta-complex is bound to transcriptionally active non-coding RNA loci together with leucine zipper motif-containing protein 1 in mouse embryonic stem cells. (A) Two genome-wide ChIP-seq experiments were carried out in mESC using both LUZP1 and GCN5 polyclonal antibodies. The tag density over a 2 kb region around the identified LUZP1 binding sites was then compared with those of GCN5 or Pol II. The plot is usually delimited by bars representing cut-off (15 reads/kb as a cut-off value) used Oxcarbazepine in further subdivision of the data. (I) Loci bound only by LUZP1; (II) loci bound by LUZP1, GCN5 and Pol II. (B) Analysis of the functional category of the transcripts neighbouring the group II loci (500 bp). (C) Validation of the ChIP-seq data by ChIP-qPCR quantification of LUZP1CMECO binding on control loci (white bars) and loci from category I (LUZP1 only, black bars) and II (LUZP1CMECO, grey bars) using the indicated antibodies. (D) Quantification of non-coding gene expression changes on MECO subunit knockdowns. Measurements of the efficiencies of siRNA knockdowns against MECO subunits are presented in supplementary Fig S4 online. The relative levels of expression of MECO target genes after knockdown of GCN5 (light grey bars), ATAC2 (medium grey bars) and MED1 (dark grey bars) by siRNA relative to scramble siRNA (white bars) were quantified by reverse transcriptionCqPCR. Mean and standard kanadaptin deviation over three biological replicates were calculated. online (http://www.emboreports.org). Note added in proof. The natural and processed ChIP-seq datasets have been deposited in the Gene Expression Omnibus (GEO) under the accession number “type”:”entrez-geo”,”attrs”:”text”:”GSE21717″,”term_id”:”21717″GSE21717. Supplementary Material Supplementary Information:Click here to view.(489K, doc) Acknowledgments We are grateful to M. Orpinell and D. Devys for crucial reading of the paper, M. Meinsterernst for antibodies, R. Poot and M. Ballarino for guidance, A. Dierich for help in mESC culture, the IGBMC high-throughput sequencing platform, G. Duval, P. Eberlin, IGBMC purchase service for their help, and K. Bezstarosti for technical support. A.R.K. is the recipient of a fellowship from INSERM-Rgion Alsace.